SG11202112828SA - Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists - Google Patents
Pyrazole and imidazole derivatives, compositions and methods as orexin antagonistsInfo
- Publication number
- SG11202112828SA SG11202112828SA SG11202112828SA SG11202112828SA SG11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- group
- substituted
- halogen
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856822P | 2019-06-04 | 2019-06-04 | |
| PCT/US2020/035851 WO2020247447A1 (en) | 2019-06-04 | 2020-06-03 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112828SA true SG11202112828SA (en) | 2021-12-30 |
Family
ID=73651984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112828SA SG11202112828SA (en) | 2019-06-04 | 2020-06-03 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220315602A1 (https=) |
| EP (1) | EP3972587A4 (https=) |
| JP (1) | JP7837120B2 (https=) |
| KR (1) | KR20220016919A (https=) |
| CN (1) | CN114340616A (https=) |
| AU (1) | AU2020288559C1 (https=) |
| CA (1) | CA3140173A1 (https=) |
| SG (1) | SG11202112828SA (https=) |
| WO (1) | WO2020247447A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020286381C1 (en) | 2019-06-04 | 2025-07-10 | Hager Biosciences, Llc | Imidazolo derivatives, compositions and methods as orexin antagonists |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| US20260070922A1 (en) * | 2022-09-01 | 2026-03-12 | Hager Biosciences, Llc | Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders |
| CN118556061B (zh) * | 2022-11-23 | 2025-07-15 | 江苏恩华药业股份有限公司 | 一种二取代八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用 |
| GB202311281D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| GB202311280D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| CN117169393B (zh) * | 2023-11-03 | 2024-03-19 | 杭州湃肽生化科技有限公司 | 一种植物组织中环肽的检测方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925849A (en) * | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| UA85937C2 (uk) * | 2004-12-21 | 2009-03-10 | Пфайзер Продактс Інк. | Макроліди |
| AR067665A1 (es) * | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| US8614242B2 (en) * | 2010-10-21 | 2013-12-24 | Bayer Intellectual Property Gmbh | 1-(heterocyclic carbonyl)-2-substituted pyrrolidines |
| US20140228377A1 (en) * | 2011-07-05 | 2014-08-14 | Taisho Pharmaceutical Co., Ltd. | Methylpiperidine derivative |
| EP2771346A4 (en) * | 2011-10-25 | 2015-06-03 | Merck Sharp & Dohme | ISOXAZOLOPYRIDIN-orexin |
| CA2863413A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US10081624B2 (en) * | 2014-08-26 | 2018-09-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MY205440A (en) * | 2018-09-28 | 2024-10-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| AU2020286381C1 (en) * | 2019-06-04 | 2025-07-10 | Hager Biosciences, Llc | Imidazolo derivatives, compositions and methods as orexin antagonists |
-
2020
- 2020-06-03 AU AU2020288559A patent/AU2020288559C1/en not_active Expired - Fee Related
- 2020-06-03 KR KR1020217043401A patent/KR20220016919A/ko not_active Ceased
- 2020-06-03 CA CA3140173A patent/CA3140173A1/en active Pending
- 2020-06-03 SG SG11202112828SA patent/SG11202112828SA/en unknown
- 2020-06-03 EP EP20817900.2A patent/EP3972587A4/en not_active Withdrawn
- 2020-06-03 JP JP2021569992A patent/JP7837120B2/ja active Active
- 2020-06-03 CN CN202080056013.4A patent/CN114340616A/zh active Pending
- 2020-06-03 US US17/616,142 patent/US20220315602A1/en not_active Abandoned
- 2020-06-03 WO PCT/US2020/035851 patent/WO2020247447A1/en not_active Ceased
-
2024
- 2024-08-09 US US18/799,706 patent/US12275744B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7837120B2 (ja) | 2026-03-30 |
| EP3972587A1 (en) | 2022-03-30 |
| CN114340616A (zh) | 2022-04-12 |
| US20220315602A1 (en) | 2022-10-06 |
| AU2020288559C1 (en) | 2025-07-24 |
| US12275744B2 (en) | 2025-04-15 |
| WO2020247447A1 (en) | 2020-12-10 |
| US20240400580A1 (en) | 2024-12-05 |
| AU2020288559A1 (en) | 2022-01-20 |
| JP2022534709A (ja) | 2022-08-03 |
| AU2020288559A8 (en) | 2022-02-03 |
| KR20220016919A (ko) | 2022-02-10 |
| AU2020288559B2 (en) | 2025-04-17 |
| CA3140173A1 (en) | 2020-12-10 |
| EP3972587A4 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202112828SA (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
| AU2020286381B2 (en) | Imidazolo derivatives, compositions and methods as orexin antagonists | |
| AU2013327505B2 (en) | Anti-fibrotic pyridinones | |
| CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
| DK3102573T3 (en) | Substituted thiazole or oxazole P2X7 receptor antagonists | |
| BR112018002304B1 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| EP3715341A1 (en) | Halo-allylamine ssao/vap-1 inhibitor and use thereof | |
| EP4423068B1 (en) | Rxfp1 agonists | |
| WO2024044351A2 (en) | Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders | |
| JP2018513199A (ja) | イミダゾール系化合物 | |
| WO2025188753A1 (en) | Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders | |
| TW202115023A (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 | |
| JP2024542036A (ja) | Ｇｐｒ３９タンパク質のアンタゴニスト | |
| HK40028252A (en) | Halo-allylamine ssao/vap-1 inhibitor and use thereof | |
| CN101959883A (zh) | 3-吲唑基-4-吡啶基异噻唑类化合物 |